Ann-Cathrine Larsen1,2, Christina Dahl3, Christina M Dahmcke3, Johanne Lade-Keller4, Volkert D Siersma5, Peter B Toft6, Sarah E Coupland7, Jan U Prause1, Per Guldberg3, Steffen Heegaard2,6. 1. Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark. 2. Department of Pathology - Rigshospitalet, Copenhagen, Denmark. 3. Danish Cancer Society, Research Center, Copenhagen, Denmark. 4. Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark. 5. The Research Unit and Section of General Practice, Institute of Public Health, University of Copenhagen, Copenhagen, Denmark. 6. Department of Ophthalmology, Rigshospitalet - Glostrup Hospital, Copenhagen, Denmark. 7. Division of Pathology, Department of Molecular and Clinical Medicine, Royal Liverpool University Hospital, Liverpool, UK.
Abstract
PURPOSE: To investigate incidence, clinicopathological features and prognosis of BRAF-mutated conjunctival melanoma in Denmark. Furthermore, to determine BRAF mutations in paired premalignant lesions and evaluate immunohistochemical BRAF V600E oncoprotein detection. METHODS: Data from 139 patients with conjunctival melanoma (1960-2012) were collected. Archived conjunctival melanoma samples and premalignant lesions were analysed for BRAF mutations using droplet digital polymerase chain reaction (PCR). Results were associated with clinicopathological features and compared with BRAF V600E oncoprotein stainings. RESULTS: The overall incidence of conjunctival melanoma (0.5 cases/1 000 000/year) increased during the study period with 0.13 cases/1 000 000/10 years. The increase comprised a higher proportion of patients aged >65 years, epibulbar tumours and tumours developed from a primary acquired melanosis with atypia. BRAF mutations were identified in 39 of 111 (35%) cases. The rate ratio of BRAF-mutated versus BRAF-wild-type melanoma did not change over time. BRAF mutations were associated with T1 stage (p = 0.007), young age (p = 0.001), male gender (p = 0.02), sun-exposed location (p = 0.01), mixed/non-pigmented tumour colour (p = 0.02) and nevus origin (p = 0.005), but did not associate with prognosis. BRAF status in conjunctival melanoma and paired premalignant lesions corresponded in 19 of 20 cases. Immunohistochemistry detected BRAF V600E mutations with a sensitivity of 0.94 and a specificity of 1.00 in newer conjunctival melanoma samples (2000-2012, n = 47). CONCLUSION: The incidence of conjunctival melanoma increased in Denmark over 50 years. The proportion of BRAF-mutated conjunctival melanoma was constant. BRAF mutations were identified as early events in conjunctival melanoma, associated with a distinct clinicopathological profile, similar to BRAF-mutated cutaneous melanoma. Immunohistochemical detection of BRAF can be used to assess BRAF V600E mutations.
PURPOSE: To investigate incidence, clinicopathological features and prognosis of BRAF-mutated conjunctival melanoma in Denmark. Furthermore, to determine BRAF mutations in paired premalignant lesions and evaluate immunohistochemical BRAFV600E oncoprotein detection. METHODS: Data from 139 patients with conjunctival melanoma (1960-2012) were collected. Archived conjunctival melanoma samples and premalignant lesions were analysed for BRAF mutations using droplet digital polymerase chain reaction (PCR). Results were associated with clinicopathological features and compared with BRAFV600E oncoprotein stainings. RESULTS: The overall incidence of conjunctival melanoma (0.5 cases/1 000 000/year) increased during the study period with 0.13 cases/1 000 000/10 years. The increase comprised a higher proportion of patients aged >65 years, epibulbar tumours and tumours developed from a primary acquired melanosis with atypia. BRAF mutations were identified in 39 of 111 (35%) cases. The rate ratio of BRAF-mutated versus BRAF-wild-type melanoma did not change over time. BRAF mutations were associated with T1 stage (p = 0.007), young age (p = 0.001), male gender (p = 0.02), sun-exposed location (p = 0.01), mixed/non-pigmented tumour colour (p = 0.02) and nevus origin (p = 0.005), but did not associate with prognosis. BRAF status in conjunctival melanoma and paired premalignant lesions corresponded in 19 of 20 cases. Immunohistochemistry detected BRAFV600E mutations with a sensitivity of 0.94 and a specificity of 1.00 in newer conjunctival melanoma samples (2000-2012, n = 47). CONCLUSION: The incidence of conjunctival melanoma increased in Denmark over 50 years. The proportion of BRAF-mutated conjunctival melanoma was constant. BRAF mutations were identified as early events in conjunctival melanoma, associated with a distinct clinicopathological profile, similar to BRAF-mutated cutaneous melanoma. Immunohistochemical detection of BRAF can be used to assess BRAFV600E mutations.
Authors: Swarup S Swaminathan; Matthew G Field; David Sant; Gaofeng Wang; Anat Galor; Sander R Dubovy; J William Harbour; Carol L Karp Journal: JAMA Ophthalmol Date: 2017-12-01 Impact factor: 7.389
Authors: Niels J Brouwer; Marina Marinkovic; Anouk Jochems; Ellen W Kapiteijn; Sjoerd G van Duinen; Barbara I Haeseker; Martine J Jager; Gregorius P M Luyten Journal: Ocul Oncol Pathol Date: 2017-09-01
Authors: Natasha M van Poppelen; Jolique A van Ipenburg; Quincy van den Bosch; Jolanda Vaarwater; Tom Brands; Bert Eussen; Frank Magielsen; Hendrikus J Dubbink; Dion Paridaens; Erwin Brosens; Nicole Naus; Annelies de Klein; Emine Kiliç; Robert M Verdijk Journal: Int J Mol Sci Date: 2021-05-28 Impact factor: 5.923
Authors: S L Scholz; I Cosgarea; D Süßkind; R Murali; I Möller; H Reis; S Leonardelli; B Schilling; T Schimming; E Hadaschik; C Franklin; A Paschen; A Sucker; K P Steuhl; D Schadendorf; H Westekemper; K G Griewank Journal: Br J Cancer Date: 2018-03-21 Impact factor: 7.640